drugset
drugset / Trial / NCT06171061

Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome

NCT06171061 ↗

Phase 4 Recruiting 1200 enrolled Shandong First Medical University
RandomizedParallel-groupSingle-blindTreatment

Summary

This study is a prospective, multicentre, randomized, open-label, blinded-endpoint clinical trial to evaluate the efficacy and safety of Yangxinshi tablets in the treatment of patients with chronic coronary syndrome (CCS).

Timeline

Start
2023-12-18
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Yangxinshi Traditional medicine (herbal / TCM) 3 unknown —

Indications

coronary artery disorder